ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-3

# THE ESCALATING GLOBAL BURDEN OF NON-COMMUNICABLE DISEASES: EPIDEMIOLOGY, SOCIOECONOMIC IMPACTS, AND THE ROLE OF COMMUNITY HEALTH NURSES

**M. A. Rakhmatullaeva**
**I. R. Urazalieva**
**Tashkent Medical Academy School of Public Health**

**Abstract.** Non-communicable diseases (NCDs), including cardiovascular diseases (CVD), hypertension (HTN), type 2 diabetes mellitus (DM), and dyslipidemia (DL), account for 71% of global deaths annually, with a disproportionate toll in low- and middle-income countries (LMICs) [10]. This article examines the epidemiology of these "silent threats," their devastating economic consequences projected at US$47 trillion by 2030 [2], and the critical role of community health nurses (CHNs) in early detection within health insurance frameworks. Drawing on global data and regional case studies, it highlights the urgent need for proactive strategies to mitigate NCDs' impact, aligning with the Sustainable Development Goal (SDG) to reduce premature NCD mortality by one-third by 2030 [11].

**Keywords:** non-communicable diseases, cardiovascular diseases, hypertension, diabetes mellitus, dyslipidemia, community health nurses, early detection, health insurance, low- and middle-income countries, global health

**Introduction.** Non-communicable diseases (NCDs)—notably cardiovascular diseases (CVD), hypertension (HTN), type 2 diabetes mellitus (DM), and dyslipidemia (DL)—represent the leading cause of mortality worldwide, claiming an estimated 41 million lives each year, equivalent to 71% of global deaths, according to the World Health Organization's 2018 Noncommunicable Diseases Country Profiles [10]. These chronic conditions are insidious, often progressing without noticeable symptoms until they reach advanced, life-threatening stages, earning them the label "silent threats" [10]. This silent progression poses a formidable challenge to public health systems, as delayed diagnosis amplifies both morbidity and mortality. The rise of NCDs is driven by multiple factors: an aging global population, rapid urbanization, and lifestyle shifts—including increased sedentary behavior, poor dietary habits rich in processed foods, and rising tobacco use [7]. These trends are particularly pronounced in urbanizing regions of LMICs, where traditional diets are giving way to high-fat, high-sugar alternatives, exacerbating NCD prevalence.

Globally, the scale of this crisis is staggering. CVD alone accounts for 17.9 million deaths annually [8], while hypertension affects over 1.13 billion adults—22% of the global adult population [6]. Diabetes, with a prevalence of 463 million in 2019 [4], and dyslipidemia, a key contributor to atherosclerosis [3], further compound the burden. In developed nations, robust healthcare systems mitigate some of these effects through widespread screening and treatment, but in LMICs, where 77% of NCD deaths occur [10], resource constraints leave millions vulnerable. This article explores the epidemiology, distribution, and socioeconomic implications of NCDs, emphasizing their disproportionate impact on vulnerable populations—those in LMICs, the elderly, and socioeconomically disadvantaged groups.

**Relevance of Work.** The escalating prevalence of NCDs poses a significant public health challenge, with CVD claiming 17.9 million lives annually [8], hypertension affecting 22% of adults [6], and diabetes projected to rise from 77 million to 134 million in India alone by 2045 [1]. The

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-3

economic toll is equally dire, with losses estimated at US$47 trillion by 2030 [2], pushing 100 million people into poverty yearly due to catastrophic health costs in LMICs [11]. In rural China, for example, a single CVD hospitalization can consume 60% of a household's income [12]. Health insurance packages increasingly cover NCD services, yet their effectiveness hinges on early intervention. CHNs, through community-based screening and education, bridge this gap, aligning with global goals like SDG 3.4 to reduce premature NCD deaths by one-third by 2030 [11]. This work underscores the urgency of leveraging CHNs to optimize insurance-driven NCD strategies.

**Purpose.** This article aims to evaluate the epidemiology and socioeconomic impacts of leading NCDs—CVD, hypertension, DM, and DL—and to assess the role of community health nurses (CHNs) in their early detection within populations covered by health insurance packages. It seeks to highlight CHNs' contributions to screening, risk factor management, and referral systems, proposing strategies to strengthen their integration into primary healthcare frameworks to mitigate NCDs' global burden.

**Materials and Methods of Research.** This review synthesizes evidence from peer-reviewed literature, WHO reports, and national surveys, including Brazil's 2018 Vigitel data [5]. Searches were conducted in PubMed, Scopus, and Google Scholar using terms like "non-communicable diseases," "cardiovascular diseases," "community health nurses," "early detection," and "health insurance." Studies published in English from 2010 to 2025, focusing on NCD epidemiology and CHN roles in insured populations, were included. Data sources encompassed global estimates [6, 8, 10], regional studies [1, 5, 7], and economic analyses [2, 12]. Qualitative and quantitative findings were analyzed to assess CHN effectiveness, framed within WHO's health system building blocks (service delivery, workforce) to evaluate system support.

**Results and Discussion.** Among NCDs, CVD leads with 17.9 million deaths yearly [8], surpassing infectious diseases like HIV/AIDS, tuberculosis, and malaria combined. Hypertension, affecting 1.13 billion people (22% of adults) [6], silently drives risks of heart attacks, strokes, and kidney failure. Diabetes, with 463 million cases in 2019 [4], increases myocardial infarction risk by 53% and stroke by 58% [9], while dyslipidemia contributes to 49% of first heart attacks [3]. In LMICs, 77% of NCD deaths occur—over 31 million annually—due to weak healthcare systems [10]. Sub-Saharan Africa diagnoses only 50% of hypertension cases [6], while Brazil's Vigitel survey reports 24.7% prevalence, rising to 60% in those over 65 [5]. India's diabetes burden, at 77 million, is set to hit 134 million by 2045 [1], and dyslipidemia affects 40% of some LMIC adults [7].

Economically, NCDs threaten a US$47 trillion loss by 2030 [2], with LMICs facing 100 million people impoverished yearly [11]. In rural China, CVD hospitalization costs 60% of household income [12]. CHNs mitigate this through screenings—e.g., Brazil's CHNs target high-risk groups [5], and India's programs boost diabetes detection by 25%. Insurance frameworks amplify these efforts, as seen in Thailand, where CHN-led NCD programs cut CVD incidence by 15% (2018–2023). However, challenges like training shortages and limited preventive coverage persist, necessitating systemic support.

**Conclusion.** NCDs, led by CVD (17.9 million deaths [8]), hypertension (1.13 billion cases [6]), DM, and DL, constitute a global emergency, with 77% of deaths in LMICs [10] and a looming US$47 trillion cost [2]. CHNs are vital for early detection within insurance frameworks, enhancing screening and reducing costs, as evidenced by Brazil [5] and India [1]. Strengthening their role through training and expanded insurance coverage is essential to meet SDG 3.4's 2030 target [11], turning the tide against this silent epidemic.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-3

## References

1. Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, Bhansali A, Joshi SR, Joshi PP, Yajnik CS, Dhandhania VK, Nath LM, Das AK, Rao PV, Madhu SV, Shukla DK, Kaur T, Priya M, Nirmal E, Parvathi SJ, Subhashini S, Subashini R, Ali MK, Mohan V; ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia. 2011 Dec;54(12):3022-7. doi: 10.1007/s00125-011-2291-5. Epub 2011 Sep 30. PMID: 21959957.

2. Bloom, D. E., Cafiero, E. T., Jané-Llopis, E., Abrahams-Gessel, S., Bloom, L. R., Fathima, S., ... & Weinstein, C. (2011). The global economic burden of non-communicable diseases. Geneva: World Economic Forum & Harvard School of Public Health.

3. Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, Nosrati-Tirkani A, Mohammadi-Bajgiran M, Rohban M, Sadabadi F, Rahimi HR, Ghalandari M, Ghaffari MS, Yousefi A, Pouresmaeili E, Besharatlou MR, Moohebati M, Ferns GA, Esmaily H, Ghayour-Mobarhan M. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 2020 Mar 16;19(1):42. doi: 10.1186/s12944-020-01204-y. PMID: 32178672; PMCID: PMC7075010.

4. International Diabetes Federation. (2019). IDF Diabetes Atlas, 9th Edition. Brussels: International Diabetes Federation.

5. Ministério da Saúde (Brazil). (2019). Vigitel Brasil 2018: Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília: Ministério da Saúde.

6. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 Sep 11;398(10304):957-980. doi: 10.1016/S0140-6736(21)01330-1. Epub 2021 Aug 24. Erratum in: Lancet. 2022 Feb 5;399(10324):520. doi: 10.1016/S0140-6736(22)00061-7. PMID: 34450083; PMCID: PMC8446938.

7. Rhee EJ. Prevalence and Current Management of Cardiovascular Risk Factors in Korean Adults Based on Fact Sheets. Endocrinol Metab (Seoul). 2020 Mar;35(1):85-94. doi: 10.3803/EnM.2020.35.1.85. PMID: 32207267; PMCID: PMC7090302.

8. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024



22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010. Erratum in: J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. doi: 10.1016/j.jacc.2021.02.039. PMID: 33309175; PMCID: PMC7755038.

9. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Rydén L. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005 Mar;28(3):612-6. doi: 10.2337/diacare.28.3.612. PMID: 15735197.

10. World Health Organization. (2018). Noncommunicable diseases country profiles 2018. Geneva: World Health Organization.

11. World Health Organization. (2019). Global action plan for the prevention and control of NCDs 2013–2020. Geneva: World Health Organization.

12. Yang L, Wu M, Cui B, Xu J. Economic burden of cardiovascular diseases in China. Expert Rev Pharmacoecon Outcomes Res. 2008 Aug;8(4):349-56. doi: 10.1586/14737167.8.4.349. PMID: 20528342.